Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon α2β after intensive therapy

British Journal of Cancer

Volumn 73, Issue 2, 1996, Pages 236-240

  Millar, B C ^a   Bell, J B G ^a   Powles, R L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

B cell; Immune recovery; Interferon 2 ; Multiple myeloma; NK activity

Indexed keywords

CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MELPHALAN; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MELPHALAN; MULTIPLE MYELOMA; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; RECURRENCE; REMISSION INDUCTION; STATISTICS, NONPARAMETRIC;

EID: 0030033381     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.41     Document Type: Article

References (27)

1. ABBAS AK. (1979). T-lymphocyte-mediated suppression of myeloma function in vitro. I. Suppression by allogeneically activated T-lymphocytes. J. Immunol., 123, 2011-2018.
2. ATTAL M, HUGUET F, SCHLAIFER D, PAYEN C, LAROCHE M, FOURNIE B, MAZIERES B, PRIS J AND LAURENT G. (1992). Intensive combined therapy for previously untreated aggressive myeloma. Blood, 79, 1130-1136.
3. BERGMANN L, MITRON PS, WEBER KC, KELKER W. (1984). Imbalances of T-cell subsets in monoclonal gammopathies. Cancer Immunol. Immunother., 17, 112-116.
4. BOYUM A. (1968). Separation of leucocytes from blood and bone marrow. Scand. J. Clin. Lab. Invest., 21, 1-6.
5. CIMINO G, AVVISATA G, AMADORI S, CAVA MC, GIANARELLI D, DINUCCI GD, MAGLIOCCI V, PETRUCCI MT, POTI G, SGADARI C AND MANDELLI F. (1990). High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br. J. Haematol., 75, 373-377.
6. CUNNINGHAM D, POWLES R, MALPAS JS, MILAN S, MELDRUM M, VINER C, MONTES A, HICKISH T, NICOLSON M, JOHNSON P, MANSI J, TRELEAVEN J, RAYMOND J AND GORE ME. (1993). A randomised trial of maintenance therapy with Intron A following high dose melphalan and ABMT in myeloma. Br. J. Cancer, 67 (suppl.XX), 30.
7. DIANZANI U, PIERI A, BOCCADORO M, PALUMBO A, PIOPPO P, BIANCHI A, CAMPONI A, BATTAGLIO S AND MASSAIA M. (1988). Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies; correlation with diagnosis and disease status. Blood 72, 1064-1068.
8. EINHORN S, AHRE A, BLOMGREN H, JOHANSSON B AND MELLSTEDT H. (1982). Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-α. Int. J. Cancer, 30, 167-172.
9. + T-cell subset with unrestricted cytokine profile. J. Immunol., 143, 518-525.
10. GONZALEZ M, SAN MIGUEL JF, GASCON A, MORO MJ, HERNANDEZ JM, ORTEGA F, TIMENEZ R, GUERRAS L, ROMERO M, CASANOVA F, SANZ MA, PORTERO JA AND ORFAO A. (1992). Increased expression of natural killer associated and activation antigens in multiple myeloma. Am. J. Hematol., 37, 84-89.
11. JOSHUA DE. (1988). Biology of multiple myeloma. Host tumour interactions and immunoregulation of disease activity. Hematol. Oncol., 6, 83-88.
12. 2β) early after bone marrow transplantation in patients at high risk for relapse. Blood, 78, 3306-3311.
13. MASSAIA M, DIAZANI U, BIANCHI A, CAMPONI A, BOCCADORO M AND PILERI A. (1988). Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clin. Exp. Immunol., 73, 214-218.
14. MASSAIA M, BIANCHI A, DIAZANI U. (1989). Defective interleukin 2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. Clin. Exp. Immunol., 79, 100-104.
15. MASSAIA M, ATTISANO C, PEOLA S, MONTACCHINI L, OMEDE P, CORRADINI F, FERRERO D, BOCCADORO M, BIANCHI A AND PILERI A. (1993). Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3 activated T-cells. Blood, 82, 1787-1797.
16. 2β. Br. J. Cancer, 72, 1525-1530.
17. MONTES BORINAGA A. (1993). Biological studies with growth factors in multiple myeloma; the effect of IL-6 and alpha interferon on the proliferation of multiple myeloma in vitro and the clinical efficacy of alpha interferon in vivo. MD Thesis, Universidad del Pais Vasco, Leioa, Mayo, Spain.
18. OSTERBORG A, NILSSON B, BJORKHOLM M, HOLM G AND MELLSTEDT H. (1990). Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur. J. Haematol., 45, 153-157.
19. 2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy. Cancer Immunol. Immunother., 34, 157-162.
20. PARRONCHI P, DECARLI M, MANETTI R, SIMONELLI C, SAMPOGNAROS S, PICCINI MP, MACCHIA E, MAGGI E, DEL PRETE G AND ROMAGNANI S. (1992). IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by TH-1 and TH-2 human T-cell clones. J. Immunol., 149, 2977-2983.
21. RALPH QM, BRISCO MJ, JOSHUA DE, BROWN R, GIBSON J AND MORLEY AA. (1993). Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: Evidence from the Ig heavy chain gene. Blood, 82, 202-206.
22. ROHRER JW AND LYNCH RG. (1979). Immunoregulation of localised and disseminated multiple myeloma: antigen-specific regulation of MOPC 315 stem cell proliferation and secretory cell differentiation. J. Immunol., 123, 1083-1087.
23. ROMAGNINI S. (1992). Induction of Th1 and Th2 responses: a key role for the 'natural' immune response? Immunol. Today., 13, 379-381.
24. SAHOTA S, HAMBLIN T, OSCIER DG AND STEVENSON FK. (1994). Assessment of the role of clonogenic B lymphocytes in the pathogenesis of multiple myeloma. Leukemia, 8, 1285-1289.
25. SAN MIGUEL JF, GONZALEZ M, GASCON A, MORO MJ, HERNANDEZ JM, ORTEGA F, JIMENEZ R, GUERRAS L, ROMERO M AND CASANOVA F. (1992). Lymphoid subsets and prognosis factors in multiple myeloma. Cooperative group for the study of monoclonal gammopathies. Br. J. Haematol., 80, 305-309.
26. UCHIDA AA, YAGITA M, SUGIYAMA H, HOSHINO T AND MOORE M. (1984). Strong natural killer (NK) cell activity in bone marrow of myeloma patients: Accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int. J. Cancer, 34, 375-381.
27. VACCA A, DI STEFANO R, FRASSANITO A, IODICE G AND DAMMACCO F. (1991). A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma. Clin. Exp. Immunol., 84, 429-434.